Pharmacokinetics and tissue distribution study of novel potent antiplatelet agent S007-867 in mice using HPLC-MS/MS. (June 2015)

• Record Type: Journal Article
• Authors: Chandasana, Hardik; Chhonker, Yashpal S.; Prasad, Yarra Durga; Laxman, Tulsankar Sachin; Anil Kumar, K. S.; Dikshit, Dinesh K.; Bhatta, Rabi S.
• Is Part Of: Xenobiotica. Volume 45:Number 6(2015:Jun.)
• Page Start: 530
• Page End: 537
• Publication Date: 2015-06
• Subjects: Metabolism -- Periodicals; Drugs -- Physiological effect -- Periodicals; Food additives -- Periodicals; Chemicals -- Physiological effect -- Periodicals; Biochemistry -- Periodicals; Pharmaceutical Preparations -- metabolism -- Periodicals; Metabolism -- Periodicals; 574.133
• DOI: 10.3109/00498254.2014.994053
• Languages: English
• ISSNs: 0049-8254

Abstract

<abstract> <title>Abstract</title> <p>1. S007-867 is a novel antiplatelet agent that shows promising <italic>in vitro</italic> and <italic>in vivo</italic> efficacy. For further development and better pharmacological elucidation, we characterized pharmacokinetics and tissue distribution of S007-867 in a mouse model.</p> <p>2. A sensitive, selective and robust LC-MS/MS method was developed and validated in the mouse plasma and tissue for quantification of S007-867. The chromatographic separation was performed on Waters Symmetry Shield C18 column (150 × 4.6 mm, 5 µm) using methanol and ammonium acetate buffer.</p> <p>3. S007-867 was rapidly absorbed and distributed to various tissues. Following single oral administration of S007-867 in the mouse, the concentration was in the order of C intestine &gt; C liver &gt; C kidney &gt; C heart &gt; C spleen &gt; C lungs &gt; C brain. Tissue to plasma area under the plasma curve ratio suggested that the maximum amount of drug was found in the intestine and liver. Half life of S007-867 was found longer in the heart (8.08 h), spleen (∼ 7.94 h) and kidney (∼ 15.41 h) as compared with other tissues.</p> <p>4. The preclinical pharmacokinetics and tissue distribution data obtained using this LC-MS/MS method are expected to assist the future clinical investigations of S007-867 as a promising antiplatelet agent.</p> </abstract>